This submission by Monsanto makes a joke of biosafety risk assessment in that it is not based on the actual event under consideration, but rather, the applicant posits claim of lack of harm, toxicity, and allergenicity based on data carried out on other lines containing the same transgene/event. This violates the case by case approach to GMO risk assessment enshrined in the GMO Act 1997. It also lacks sufficient scientific data to support claims of safety and this is exacerbated by lack of peer reviewed information on this event. In addition, the applicant has not considered the health impacts of the herbicide to which this event is engineered to tolerate. Furthermore, approval of this commodity import is likely to significantly impact upon commercial and emerging maize producers, and could have further impacts along the value chain. There are other issues affecting animal feed producers and consumers (the continuation of cheap chicken imports from the EU, for example), the resolution of which would do more to strengthen South Africa?s agricultural sector. It is the opinion of the ACB that this application should be rejected on both biosafety and socio-economic grounds.